SLC5A2 and hydrops fetalis: Results from recent cardiovascular outcome trials have suggested that the benefits of sodium-glucose cotransporter 2 (SGLT) inhibitors (e.g., dapagliflozin, empagliflozin and canagliflozin) derived by patients with HF can be attributed to an improvement in renal function (5–8).